|
|
T A Graubert, J F DiPersio, J H Russell, T J Ley
J Clin Invest. 1997;
100(4):904
doi:10.1172/JCI119606
Abstract |
Full text
| PDF

G
raft-versus-host disease (GvHD) is the major limiting toxicity of allogeneic bone marrow transplantation. T cells are important mediators of GvHD, but the molecular mechanisms that they use to induce GvHD are controversial. Three effector pathways have been described for cytotoxic T lymphocytes: one requires perforin and granzymes, the second Fas (APO-1; CD95) and its ligand. Thirdly, secreted molecules (e.g., TNF-alpha, gamma-IFN) can also mediate cytotoxicity. Together, these mechanisms appear to account for virtually all cytotoxicity induced by activated CTL in standard in vitro lytic assays. Using transplants across histocompatibility barriers, we were able to analyze the contributions of these effector molecules to cell-mediated cytotoxicity in vivo in a GvHD model. We found that Fas ligand is an important independent mediator of class II-restricted acute murine GvHD, while perforin/granzyme-dependent mechanisms have only a minor role in that compartment. In contrast, perforin/ granzyme-dependent mechanisms are required for class I-restricted acute murine GvHD, while Fas ligand is not. The perforin/granzyme pathway may therefore represent a novel target for anti-GvHD drug design. In support of this approach, we provide additional data suggesting that specific perforin/granzyme inhibitors should not adversely affect hematopoietic recovery after transplantation.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(50)
| Title and authors |
Publication |
Year |
Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes
K. L. Hippen, C. Bucher, D. K. Schirm, A. M. Bearl, T. Brender, K. A. Mink, K. S. Waggie, R. Peffault de Latour, A. Janin, J. M. Curtsinger
|
Blood
|
2012 |
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice
Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping Chen, Bruce R. Blazar, Xue-Zhong Yu
|
Biology of Blood and Marrow Transplantation
|
2011 |
Cytolytic CD4+T cells in viral immunity
Damien Z Soghoian, Hendrik Streeck
|
Expert Rev Vaccines
|
2010 |
Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease
Y. Zhang, A. R. Sandy, J. Wang, V. Radojcic, G. T. Shan, I. T. Tran, A. Friedman, K. Kato, S. He, S. Cui, E. Hexner, D. M. Frank, S. G. Emerson, W. S. Pear, I. Maillard
|
Blood
|
2010 |
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease
J. A. Rotolo, B. Stancevic, S. X. Lu, J. Zhang, D. Suh, C. G. King, L. W. Kappel, G. F. Murphy, C. Liu, Z. Fuks, M. R. van den Brink, R. Kolesnick
|
Blood
|
2009 |
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation
C. Bucher, L. Koch, C. Vogtenhuber, E. Goren, M. Munger, A. Panoskaltsis-Mortari, P. Sivakumar, B. R. Blazar
|
Blood
|
2009 |
IL-21 is critical for GVHD in a mouse model
A Meguro, K Ozaki, I Oh, K Hatanaka, H Matsu, R Tatara, K Sato, W J Leonard, K Ozawa
|
Bone Marrow Transplant
|
2009 |
Cytolytic molecules in rejection
Carol Clayberger
|
Current Opinion in Organ Transplantation
|
2009 |
Role of perforin-mediated cell apoptosis in murine models of infusion-induced bone marrow failure
Annahita K. Sarcon, Marie J. Desierto, Wenjun Zhou, Valeria Visconte, Federica Gibellini, Jichun Chen, Neal S. Young
|
Experimental Hematology
|
2009 |
Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma
W R Drobyski, P Hari, C Keever-Taylor, R Komorowski, W Grossman
|
Bone Marrow Transplant
|
2008 |
|